Izotropic Corporation focuses on developing diagnostic products, particularly the IzoView CT imaging device for breast cancer detection. A major concern is the extremely low current ratio of 0.08, indicating significant liquidity issues, alongside a troubling return on assets of -757.1%, suggesting inefficiency in asset utilization. However, the recent price increase of 3.23% may reflect growing interest or optimism in the company's potential. Overall, while the innovative focus is promising, financial health raises significant red flags that investors should consider.
Loading financial metrics...
Company has $274K in cash but burned $159K last quarter. At this burn rate, only 1.7 quarters of runway remain without additional financing.
Company posted a loss of $-3.1M over the last year, representing Infinity% of revenue.
Debt of $2.8M is 10.1x the company's cash position of $274K.
Operating cash flow has been negative for 3 consecutive quarters, burning $636K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Diagnostics & Research companies of a similar size
Based on 2025-FY (April 30, 2025)